$PGNY

Cummings Melissa B sold $71K of PGNY

Cummings Melissa B (Chief Operating Officer) sold 2,244 shares of Progyny, Inc. (PGNY) at $31.60 on 2026-07-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cummings Melissa B
Published Jul 16, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PGNY
Neutral
high confidence
Mentioned
$PGNY
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGNYNeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not include new guidance, litigation, financing, or operational milestones.

02

Market read

Traders may note insider selling, but the 10b5-1 pre-arranged nature and modest dollar value limit trading impact.

03

What to watch

The sale size ($70.9K) is relatively small versus typical institutional flows, and the 10b5-1 structure suggests timing is pre-set rather than information-driven.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-16, disclosing a 2026-07-14 insider sale.

Background

The article is a SEC Form 4 insider transaction disclosure for Progyny, Inc.

Company-level read

Ticker impact

$PGNYNeutralHigh confidence
Context

Progyny COO Melissa B Cummings sold 2,244 shares on 2026-07-14 under a pre-arranged 10b5-1 plan, totaling about $70.9K.

Expected impact

Low likelihood of a sustained price move based solely on this Form 4 sale.

Evidence & confidence

The filing specifies an open-market sale code S and confirms a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal, as the disclosure is company-specific and not tied to operational or regulatory developments.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so some traders may treat it as a mild negative sentiment input.

Key entities

  • Progyny, Inc.

    Company whose COO insider sale is disclosed via SEC Form 4.

  • Melissa B. Cummings

    Chief Operating Officer who sold 2,244 shares under a pre-arranged 10b5-1 plan.

Related articles

$PGNYMedAI 8/10

Why Progyny (PGNY) Shares Are Sliding Today

Progyny (PGNY) shares fell about 4.5% after the fertility benefits company issued weaker guidance. Q2 revenue rose to $350.5M (+5.3% YoY) and adjusted EPS was $0.55, both above estimates. But it projected $340M revenue for the next quarter, about 3% below consensus, and cut full-year revenue to $1.37B from $1.39B.

$PGNYMed

Why Progyny Stock Plunged, Then Gradually Recovered Today

Progyny (PGNY) shares fell about 6% after its Q2 earnings. The company reported 5% sales growth, with adjusted EPS up 15% versus expectations. Q3 sales guidance calls for 7% to 11% growth and adjusted earnings are slightly lower sequentially. Gross margins rose 180 bps and covered members increased 7% to 7.2 million.

$PGNYMed

Progyny, Inc. (PGNY): Results of Operations and Financial Condition

Progyny, Inc. (PGNY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026.htm EX-99.1 Document Progyny, Inc. Announces Second Quarter 2026 Results Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDA Robust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building Solutions V

$PGNYMed

Progyny (PGNY) Stock Is Up, What You Need To Know

Progyny (PGNY) shares rose 3.5% to $31.73 after KeyBanc raised its price target to $35 from $30 and kept an Overweight rating, citing expectations for a strong earnings report and higher future guidance. The article also notes other bullish analyst actions, including Truist raising its target and Canaccord upgrading to Buy.

$PGNYMedAI 8/10

A Progyny (PGNY) Insider Sold 5,500 Shares for $137,000

Progeny (PGNY) director Kevin Gordon sold 5,500 shares for about $137,000, according to the article. The firm reported Q1 revenue of $328 million, up 1.4% YoY, with gross profit rising 10% to $83.1 million. It said client growth and retention were strong aside from a large client loss, and approved a $200 million share repurchase program.